Trump, Hims & hers health
Shares in Hims Hers Health Inc (NYSE:HIMS) fell Friday after Citigroup (NYSE:C) analysts downgraded the stock to Sell/High Risk, citing overvaluation concerns tied to its GLP-1 revenue stream.
What initially stands out to me about Hims & Hers is the company's distinct branding and feel of luxury, which is evident on ...
Shares of Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) have been given a consensus recommendation of “Hold” by the ...
Hims & Hers reported impressive third-quarter results in November, with earnings of 32 cents per share, far exceeding analyst expectations.
Bearish flow noted in Hims and Hers Health with 25,948 puts trading, or 1.4x expected. Most active are Mar-25 27 puts and Jan-25 26 puts, with ...
Hims & Hers' robust Q3 2024 performance, driven by a 44% increase in subscribers and 77% y/y revenue growth, underscores its ...
John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors.
Hims has become a leader in the weight loss treatment industry by offering access to men’s health solutions that are both ...
Analyst Ryan MacDonald of Needham maintained a Buy rating on Hims & Hers Health (HIMS – Research Report), boosting the price target to ...
DMR News (English) on MSN15h
Hims & Hers Makes Waves: $1 Million Donation Tied to GLP-1 SupportIn a notable move, Hims & Hers Health donated $1 million to President-elect Donald Trump’s inauguration fund, signaling its ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback